Does curcumin reduce inflammation and possibly lower raised LP (a)?
Research indicates that approximately 20% of the global population has elevated Lp(a), making it a prevalent, yet under-recognised, CVD risk factor. Despite its clinical significance, the management of elevated Lp(a) remains challenging. Standard lipid-lowering therapies, including statins, have little to no effect on Lp(a) and may even slightly increase its levels. However, emerging therapies such as PCSK9 inhibitors and innovative supplements like curcumin are shedding light on potential strategies to mitigate this risk.